Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Operating Leases (2019 - 2026)

Avanos Medical's Operating Leases history spans 7 years, with the latest figure at $20.4 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 17.07% to $20.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.4 million, a 17.07% decrease, with the full-year FY2025 number at $20.4 million, down 17.07% from a year prior.
  • Operating Leases hit $20.4 million in Q4 2025 for Avanos Medical, down from $21.4 million in the prior quarter.
  • Over the last five years, Operating Leases for AVNS hit a ceiling of $57.5 million in Q4 2021 and a floor of $20.4 million in Q4 2025.
  • Historically, Operating Leases has averaged $33.8 million across 5 years, with a median of $31.6 million in 2023.
  • Biggest five-year swings in Operating Leases: crashed 43.48% in 2022 and later increased 26.46% in 2023.
  • Tracing AVNS's Operating Leases over 5 years: stood at $57.5 million in 2021, then crashed by 43.48% to $32.5 million in 2022, then increased by 26.46% to $41.1 million in 2023, then crashed by 40.15% to $24.6 million in 2024, then decreased by 17.07% to $20.4 million in 2025.
  • Business Quant data shows Operating Leases for AVNS at $20.4 million in Q4 2025, $21.4 million in Q3 2025, and $21.8 million in Q2 2025.